Hemophilia Therapy--Navigating Speed Bumps on the Innovation Highway
- PMID: 27223151
- DOI: 10.1056/NEJMe1603419
Hemophilia Therapy--Navigating Speed Bumps on the Innovation Highway
Comment on
-
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.N Engl J Med. 2016 May 26;374(21):2044-53. doi: 10.1056/NEJMoa1511769. N Engl J Med. 2016. PMID: 27223146 Clinical Trial.
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437. N Engl J Med. 2016. PMID: 27223147 Clinical Trial.
Similar articles
-
A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437. N Engl J Med. 2016. PMID: 27223147 Clinical Trial.
-
Validation of the chromogenic Bethesda assay for factor VIII inhibitors in hemophilia a patients receiving Emicizumab.Int J Lab Hematol. 2021 Apr;43(2):e84-e86. doi: 10.1111/ijlh.13384. Epub 2020 Nov 10. Int J Lab Hematol. 2021. PMID: 33174329 Free PMC article. No abstract available.
-
Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.Haemophilia. 2019 Mar;25(2):e121-e123. doi: 10.1111/hae.13689. Epub 2019 Feb 12. Haemophilia. 2019. PMID: 30748061 No abstract available.
-
Emicizumab for hemophilia A with factor VIII inhibitors.Expert Rev Hematol. 2018 Nov;11(11):835-846. doi: 10.1080/17474086.2018.1531701. Epub 2018 Oct 10. Expert Rev Hematol. 2018. PMID: 30278802 Review.
-
Emicizumab for hemophilia A without inhibitors.Expert Rev Hematol. 2019 Jul;12(7):515-524. doi: 10.1080/17474086.2019.1624519. Epub 2019 Jun 4. Expert Rev Hematol. 2019. PMID: 31130012 Review.
Cited by
-
Emicizumab-kxwh: First Global Approval.Drugs. 2018 Feb;78(2):269-274. doi: 10.1007/s40265-018-0861-2. Drugs. 2018. PMID: 29357074 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical